Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug ...
WuXi Biologics agreed to sell an overseas vaccine facility to Merck & Co. for half a billion dollars, a move that could strengthen the company’s cash flow and margins as it navigates global ...
We cut our fair value estimate on narrow-moat-rated WuXi Biologics to HKD 24.60 per share from HKD 28.10 as we lower our project growth assumption for the next decade. We take a fresh look after ...
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...
Hosted on MSN1mon
Merck to buy vaccine plant from WuXi Biologics: reportWuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract ...
WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback